"TRIMing" the patient population to increase the benefit of mTOR inhibition

J Natl Cancer Inst. 2014 Apr 28;106(5):dju095. doi: 10.1093/jnci/dju095.

Authors

H Ian Robins¹, Mark E Burkard¹, Richard B Halberg²

Affiliations

¹ Affiliations of authors: Division of Hematology and Oncology (HIR, MEB) and Division of Gastroenterology and Hepatology (RBH), Department of Medicine, University of Wisconsin, Madison, WI.
² Affiliations of authors: Division of Hematology and Oncology (HIR, MEB) and Division of Gastroenterology and Hepatology (RBH), Department of Medicine, University of Wisconsin, Madison, WI. rbhalberg@medicine.wisc.edu.

PMID: 24777109
DOI: 10.1093/jnci/dju095

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Carrier Proteins / genetics*
Female
Humans
Intracellular Signaling Peptides and Proteins
Male
Neoplasms / drug therapy*
Neoplasms / genetics*
Tripartite Motif Proteins

Substances

Carrier Proteins
Intracellular Signaling Peptides and Proteins
TRIM44 protein, human
Tripartite Motif Proteins

Grants and funding

P30 CA014520)/CA/NCI NIH HHS/United States